GlaxoSmithKline and Dr. Reddy’s Laboratories have signed an agreement under which, GSK will transfer ownership of its penicillin manufacturing site in Bristol, TN, and rights for the Augmentin and Amoxil brands in the U.S. to Dr. Reddy’s. GSK will retain the existing rights for these brands outside the U.S. The transaction is expected to close in 1H11. Financial terms were not disclosed. Abhijit Mukherjee, president of Dr. Reddy’s Global Generics Business, said, “We are excited about th...